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A C C E P T E D M A N U S C R I P T
3 Neuropathic pain occurs in approximately one-third of patients with diabetes and is refractory to currently available analgesic drugs (Abbott et al., 2011) . This painful diabetic neuropathy (PDN) is associated with elevated levels of methylglyoxal (MG; a reactive glucose metabolite) and decreased expression and activity of glyoxalase 1 (GLO1), the major detoxification enzyme for MG (Bierhaus et al., 2012; Huang et al., 2016; Jack et al., 2012; Skapare et al., 2013; Sveen et al., 2013) . Previous studies suggest MG produces PDN by contributing to the formation of advanced glycation end-products (MG-AGEs) (Skapare et al., 2013; Sveen et al., 2013) , and/or by sensitizing pronociceptive ion channels in peripheral afferents (Andersson et al., 2013; Bierhaus et al., 2012; Griggs et al., 2017; Huang et al., 2016; Koivisto et al., 2012) . While these studies focused on the pathophysiology of peripheral sensory nerves in the type 1 form of diabetes, type 2 diabetes accounts for 90% of patients, is more frequently associated with PDN (Abbott et al., 2011) , and the mechanisms of diabetic neuropathy may differ in these two forms of diabetes (Callaghan et al., 2012a; Callaghan et al., 2012b; Feldman et al., 2017) . Furthermore, very little is known regarding the spinal mechanisms that contribute to PDN. Thus, the central mechanisms that generate and maintain PDN in type 2 diabetes is a critical gap in knowledge.
The contribution of a MG-related spinal signaling cascade to PDN in type 2 diabetes remains unknown.
Recent studies implicate both transient receptor potential ankyrin subtype 1 (TRPA1) (Andersson et al., 2013; Griggs et al., 2017; Huang et al., 2016) and adenylyl cyclase isoform 1 (AC1) (Griggs et al., 2017) in the pain evoked by intraplantar administration of MG. The contribution of a spinal adenylyl cyclase, cyclic adenosine monophosphate (cAMP), protein kinase A (PKA) pathway was identified in the Zucker Diabetic Fatty rat model of type 2 diabetes (Feng et al., 2017) , but the specific adenylyl cyclase isoform (e.g. AC1) was not identified and antagonism of spinal PKA was not tested. Furthermore, spinal AC1-cAMP signaling could be mediated not just by PKA, but also by isoform 1 or 2 of exchange protein directly activated by cAMP (Epac1/2). Both PKA and Epac1/2 are implicated in peripheral nociceptive sensitization in various pain conditions (Aley and To test the hypothesis that spinal MG signals through TRPA1, AC1, PKA, and Epac1/2 to cause PDN in type 2 diabetes, we used two experimental models of neuropathic pain. First, we targeted the spinal cord dorsal horn with intrathecal administration of MG in conventional C57BL/6J mice and tested both reflexive and affective pain-like behaviors. Second, we utilized db/db mice, a model of type 2 diabetes that develops heat hyperalgesia (Bierhaus et al., 2012; Xu et al., 2014) concordant with hyperglycemia and elevated MG (Bierhaus et al., 2012) . We determined the behavioral effects of agents that scavenge MG or promote overexpression of GLO1, used calcium imaging to assess MG-evoked central sensitization in ex vivo spinal cord slices, and evaluated the effect of intrathecal administration of inhibitors of MG, TRPA1, AC1, PKA, and Epac1/2 on pain-like hypersensitivity in the intrathecal MG and db/db models.
MATERIALS AND METHODS

Animals
Male nondiabetic control BKS (C57BLKS/J; RRID:IMSR_JAX:000662) and type 2 diabetic db/db (BKS.Cg-Dock7m+/+Leprdb/J; RRID:IMSR_JAX:000642) mice aged 6-13 wks were used. Male mice aged 8-18 wks were used for studies involving intrathecal administration of methylglyoxal to wildtype C57BL/6J (RRID:IMSR_JAX:000664) or TRPA1 and AC1 knockout mice. TRPA1-/-knockout mice (RRID:IMSR_JAX:006401) and their respective B6129PF2/J controls (RRID:IMSR_JAX:100903) were used.
Congenic AC1-/-knockout mice were maintained in-house using a heterozygote breeding strategy onto a C57BL/6J background with genotypes confirmed by tail-snip PCR.
Mice were housed 2-4 animals per cage in a temperature and humidity-controlled room on a 14-hour light | A C C E P T E D M A N U S C R I P T 5 For db/db studies, the significant difference in mass between BKS and db/db mice prevented observer blinding to subject grouping; however, blinding to drug treatment between groups was maintained. All other experiments were performed and/or quantified by an observer blinded to the subject grouping and to the drug treatment that each group received.
Drug administration and materials
Intraperitoneal (i.p.) or intrathecal (i.t.; 5-10 μL) administration of solutions was performed as previously described (Griggs et al., 2017) . Methylglyoxal (MG; M0252, Sigma-Aldrich, St. Louis, MO) and GEAP10/GERP10 (Gift from Thomas Fleming and Peter Nawroth, University Hospital of Heidelberg, Heidelberg, Germany) were diluted in 0.9% saline. HC030031 (H4415, Sigma-Aldrich) was diluted in ethanol and Tween-80 before the titration of saline and adjustment to pH 7.4. NB001 (SML0060, Sigma-Aldrich) was diluted in water. H-89 (B1427, Sigma-Aldrich), ESI-09, HJC-0350 and HJC-0197 (courtesy of Jia Zhou, The
Animals were placed on a heated surface (52.5 ± 1 °C) within an acrylic enclosure (Hotplate; Columbus Instruments, Columbus, OH). The time until hindpaw withdraw response (e.g. jumping, licking, flinching) was recorded as the heat response latency as previously described (Griggs et al., 2016) . The animal was immediately removed after paw withdraw or a cutoff of 25 s to avoid tissue injury.
Mechanical hypersensitivity
Animals were placed within a rectangular acrylic box (15x4x4 cm; 3 white opaque walls and 1 clear wall) on a steel mesh grid. The plantar surface of the ventral-medial hindpaw was stimulated with an incremental series of 8 von Frey monofilaments (Stoelting, Inc., Wooddale, IL) of logarithmic stiffness using a modified up-down method as previously described (Chaplan et al., 1994; Griggs et al., 2015b) . The calculated 50% mechanical withdraw threshold is reported.
Conditioned place avoidance testing
Conditioned place avoidance (CPA) testing in the current study was similar to our previously published methods (Griggs et al., 2015a; Griggs et al., 2017) with the following modifications. We used a threechambered CPA apparatus consisting of an acrylic enclosure with manual guillotine doors (Place Preference, San Diego Instruments, San Diego, CA; http://www.sandiegoinstruments.com/place-preference/). Printed paper was used to cover the outside of the clear box so that the sides of the middle chamber were grey and the end chambers' walls had ¾" wide black and white stripes arranged either horizontally or vertically. The horizontally striped chamber had textured flooring, the vertically striped chamber had smooth flooring, and the center chamber flooring consisted of metal rods spaced 0.5 cm apart. Several methods were employed to reduce time spent in the middle chamber: 1) An acrylic divider (13.5cm x 10.5cm x 33cm, 0.5cm thick; custom design, Regal Plastics https://www.regal-plastics.com) was placed in the center chamber to decrease its size;
2) The guillotine doors separating the end chambers from the middle chamber were covered in white paper on the side facing the middle chamber; 3) The light intensity in the end chambers was reduced to 20% of that in the middle chamber. The time spent in each chamber was quantified using a 4 x 16 photobeam array.
The CPA experiment spanned 7 days. Mice were habituated to the experimenter and handling for intrathecal injections on Days 1-2, acclimated to the CPA apparatus on Day 3, and then averaged preconditioning preferences were assessed on Days 4-5. Mice that spent greater than 80% or less than 20% of the time in any chamber were eliminated from further study due to pre-existing chamber bias (1 mouse).
During conditioning on Day 6, pairing of intrathecal saline (5 μL) in the morning was followed four hours later by injection-pairing of MG (10 µg) to the opposite chamber. To avoid negative association with the intrathecal injection process, mice were placed back in the home cage for 5 mins after each intrathecal injection, prior to being placed in one of the isolated end chambers. As previously described (Griggs et al., 2015a) , drugchamber pairings were biased and counterbalanced. On Day 7, mice were allowed open access to the entire CPA apparatus in the absence of any injections to assess postconditioning preferences.
Ratiometric imaging of calcium responses in adult spinal cord slices
Ratiometric calcium imaging of adult mouse spinal cord slices was performed as previously described (Doolen et al., 2012) and as follows. Mice were anesthetized with isoflurane and perfused transcardially with 10 ml of ice-cold sucrose-containing artificial cerebrospinal fluid (aCSF) (sucrose-aCSF) that contained in mM: NaCl 95, KCl 1.8, KH 2 PO 4 1.2, CaCl 2 0.5, MgSO 4 7, NaHCO 3 26, glucose 15, sucrose 50 kynurenic acid 1, oxygenated with 95% O 2 , 5% CO 2 ; pH 7.4. The lumbar spinal cord was rapidly (within 90 s) isolated by laminectomy from the cervical enlargement to the cauda equina, placed in oxygenated ice-cold sucrose-aCSF, cleaned of dura mater and ventral roots, and super-glued vertically to a block of 4% agar (Fisher Scientific, Pittsburgh, PA) on the stage of a Campden 5000mz vibratome (Lafayette, IN). Transverse slices (450 μm) from lumbar segments L3-L5 were cut in ice-cold sucrose-aCSF using minimum forward speed ranging from 0.03 to 1 mm/s and using maximum vibration. Dissection and slicing time was kept to a minimum to ensure slice viability.
Slices were incubated for 30 min at 32°C with Fura-2 AM (10 μM) in pluronic acid (0.1%) in oxygenated aCSF containing (in mM): NaCl 127, KCl 1.8, KH 2 PO 4 1.2, CaCl 2 2.4, MgSO 4 1.3, NaHCO 3 26, glucose 15, followed by a 20 min de-esterification period in oxygenated aCSF without Fura-2 AM or pluronic acid. Prior to imaging, slices were maintained at room temperature in oxygenated aCSF. Slices were then placed in a RC-25
recording chamber (Warner Instruments, Hamden, CT). The recording chamber was secured on a Nikon FN-1 upright microscope fitted with a 79000 ET FURA2 Hybrid filter set (Nikon Instruments, Melville, NY) and a Photometrics CoolSNAP HQ2 camera (Tucson, AZ) and perfused at 1-2 ml/min with oxygenated aCSF. Paired 340/380 images were collected using a 20x water emersion objective at 1-1.5 images per second. Relative intracellular Ca 2+ levels were determined by measuring the change in ratio of fluorescence emission at 510 nm in response to excitation at 340 and 380 nm (200 ms exposure). Calcium responses were evaluated using Nikon Elements software by creating a region of interest over the neuronal cell profiles in lamina I-II of the dorsal horn and calculating the peak magnitude of change in the ratio of fluorescence emission in response to consecutive stimulation at 340 and 380 nm. After the acclimation period, the following recording protocol was performed: 1 mM glutamate exposure for 5 s followed by at least 5 min washout, 60 s MG exposure followed by at least 5 min washout, 1 mM glutamate exposure for 5 s. In wildtype C57BL/6J mice, dose-dependent calcium responses to 0-10 mM MG are presented as the % of calcium response to 1 mM glutamate. In 6-8 wk old BKS and db/db mice, raw calcium responses after exposure to 10 mM MG are reported.
Blood glucose and HbA1c measurement
Mice were lightly restrained in a towel and the distal tail wiped with an alcohol swab. A small nick was made at the distal tip of the tail using a #11 scalpel blade. Initial bleeding was wiped clean with gauze and subsequent drops of blood were either loaded into a room temperature HbA1c cartridge and analyzed using a DCA Vantage Analyzer (Siemens, Munich, Germany), or placed on a glucose test strip in duplicate and inserted into a glucose monitor (TrueTrack, Walgreens, Deerfield, IL).
Methylglyoxal-derived advanced glycation end-products measurement
MG-AGEs in serum were measured by competitive ELISA (STA-811, Cell BioLabs, San Diego, CA) as previously described (Griggs et al., 2016) . One part serum was diluted in three parts 1x PBS to obtain values within the range of the standard curve.
Data analysis and statistics
Results were analyzed using unpaired t-test, one-way ANOVA, or repeated measures two-way ANOVA with Holm-Sidak multiple comparison correction with α=0.05. All data were analyzed using Prism 7.0 (GraphPad, La Jolla, CA) and are presented as mean ± SEM.
RESULTS
Administration of a MG scavenging peptide or GLO1 overexpression vector reduces hyperalgesia in type 2 diabetic db/db mice
The typical presentation of painful diabetic neuropathy is characterized by initial hyperalgesia and/or allodynia followed by progression to insensitivity and/or hypoalgesia (Feldman et al., 2017) . Although a relatively recent review indicates mostly behavioral hypoalgesia in db/db mice (O'Brien et al., 2014) , these studies were in mice aged 12 weeks or more. Our current studies focused on the earlier periods of heat hyperalgesia in db/db mice (Bierhaus et al., 2012; Xu et al., 2014) . First, we tested whether the development of pain-like behavior in db/db mice is associated with signs of type 2 diabetes. Figure 1A illustrates that db/db mice develop heat hypersensitivity by 7 weeks of age. Heat hypersensitivity persisted until at least 13 wks of age (Supplemental Figure 1A) . Therefore, subsequent experiments performed in the current study utilized db/db mice aged 8-13 wks, during the period of hyperalgesia, and presumably prior to the onset of hypoalgesia. Blood glucose, body weight, and glycated hemoglobin (HbA1c) were elevated in db/db mice compared to BKS controls (Supplemental Figure 1B -D) . Figure 1B illustrates elevated serum MG-AGE levels in db/db mice.
Previous studies indicate that elevated MG in diabetes might contribute to PDN (Andersen et al., 2018; Bierhaus et al., 2012; Griggs et al., 2017; Huang et al., 2016) . To determine whether endogenous MG promotes hyperalgesia in db/db mice, we used two interventions that are validated to concurrently reduce MG levels and pain-like behavior in streptozotocin mice: a MG-scavenging peptide GERP10 (Bierhaus et al., 2012; Brings et al., 2017) , or overexpression of GLO1 (Bierhaus et al., 2012) . Figure 1C illustrates that a single intraperitoneal injection of GERP10, but not its control peptide GEAP10, increased heat response latencies in db/db but not in non-diabetic BKS mice. Compared to GEAP10, GERP10 did not alter blood glucose or HbA1c
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10 levels (Supplemental Figure 2) . Figure 1D illustrates that multiple intraperitoneal injections of the GLO1 overexpression vector, but not control vector, increased heat response latencies in db/db without changing heat response latencies in BKS controls. This protocol of GLO1 overexpression vector administration doubled Glo1 activity in sciatic nerves of streptozotocin mice (Bierhaus et al., 2012) . Central sensitization, defined as increased responsiveness of nociceptive neurons in the central nervous system to their normal or subthreshold afferent input, is a critical component of neuropathic pain conditions (Woolf, 2011) and is implicated in PDN (Greig et al., 2014) . For example, the somatosensory cortex is altered 
in patients with diabetic neuropathy (Selvarajah et al., 2019) , and spinal mechanisms contribute to PDN in patients (Selvarajah et al., 2011) and type 2 diabetic rats (Feng et al., 2017; Griggs et al., 2016) . Based on the premise that chronically elevated MG in the blood of mice and patients with PDN (Andersen et al., 2018; Bierhaus et al., 2012) could act at central sites of action because MG disrupts the blood-brain barrier (Toth et al., 2014a; Toth et al., 2014b) and is cell-permeable (Allaman et al., 2015) , we hypothesized that MG drives spinal sensitization to produce PDN in type 2 diabetes.
To test this hypothesis, we first determined whether MG is sufficient to evoke not only pain-like behavior Figure 4B) . These results uncover a MG-evoked spinal (but not peripheral) sensitization that contributes to the pain of type 2 diabetes.
Third, we tested the hypothesis that MG in the spinal cord is necessary for painful diabetic neuropathy. 
Genetic or pharmacological inhibition of spinal TRPA1 reduces MG-evoked hypersensitivity
We next interrogated the signaling cascade(s) involved in spinal MG-evoked pain in non-diabetic mice, and then determined the contribution of this signaling to spinally-mediated PDN in type 2 diabetic db/db mice.
Numerous studies implicate peripheral TRPA1 channels in the mechanism of several forms of MG-related neuropathic pain, including PDN in streptozotocin-treated type 1 diabetic rats (Huang et al., 2016; Koivisto et al., 2012) , PDN in type 2 diabetic db/db mice (Wang et al., 2018) , and MG-evoked nociception and activation of peripheral sensory neurons (Andersson et al., 2013; Eberhardt et al., 2012; Griggs et al., 2017; Ohkawara et al., 2012) . 
Genetic or pharmacological inhibition of spinal AC1 reduces MG-evoked hypersensitivity
Intrathecal administration of the pan adenylyl cyclase (AC) inhibitor SQ22536 attenuates mechanical and heat hypersensitivity in type 2 diabetic Zucker Diabetic Fatty rats (Feng et al., 2017) , suggesting that AC contributes to PDN, but this study did not address which of the 9 adenylyl cyclase isoforms (AC1-9) was involved. Our previous study indicates that pain evoked by intraplantar MG requires AC1 (Griggs et al., 2017) , and AC1 in the spinal cord contributes to inflammatory and neuropathic pain (Corder et al., 2013; Wang et al., 2011 ). Therefore, we tested the hypotheses that spinal AC1 mediates MG-evoked pain by using AC1 knockout (AC1-/-) mice and an AC1 selective antagonist, NB001, in the intrathecal MG model. As illustrated in Figure   5A , intrathecal injection of MG decreased mechanical withdraw thresholds in AC1+/+ but not AC1-/-mice. As illustrated in Figure 5B , intrathecal injection of NB001 prevented mechanical hypersensitivity induced by intrathecal MG in C57BL/6J mice. 
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18 AC1-derived cAMP drives secondary messenger signaling via PKA or Epac. Previous studies indicate that PKA contributes to PDN in Zucker Diabetic Fatty rats (Feng et al., 2017) or streptozotocin mice (Tsantoulas et al., 2017) , while Epacs contribute to other types of inflammatory or neuropathic pain (Eijkelkamp et al., 2013; Gu et al., 2016; Huang and Gu, 2017; Hucho et al., 2005; Wang et al., 2013) . To test the hypotheses that spinal PKA or Epac1/2 mediate MG-induced nociception, we determined whether intrathecal administration of antagonists of PKA, Epac2, or Epac1/2 would attenuate pain-like behavior in the intrathecal MG model. Figure   6A illustrates that the PKA inhibitor H-89 attenuated MG-evoked decreases in mechanical withdraw thresholds. diabetes, we tested whether intrathecal administration of inhibitors of TRPA1, AC1, PKA, and Epac1/2 would also reduce pain-like behavior in db/db mice. Figure 7A illustrates that intrathecal administration of the TRPA1 antagonist HC030031 reversed heat hypersensitivity in db/db mice when compared to intrathecal vehicle, without altering heat response latencies in BKS controls. Figure 7B illustrates that intrathecal administration of the AC1 antagonist NB001 attenuated heat hypersensitivity in db/db mice, without altering heat response latencies in BKS controls. As Figure 7C illustrates, the PKA antagonist H-89 did not change heat response latencies in db/db mice. Heat response latencies in BKS control mice after intrathecal administration of vehicle or H-89 were also similar (Supplemental Figure 5) . Figure 7D illustrates that the Epac1/2 inhibitor HJC-0197 but not the Epac2 selective inhibitor HJC-0350 attenuated heat hypersensitivity in db/db mice. There was no effect in BKS at any timepoint tested [NB001 dose in BKS; F(2,9) = 0.907; p = 0.44] (n=4; two-way ANOVA 
Endogenous MG is necessary for painful diabetic neuropathy in type 2 diabetes
Elevated methylglyoxal is a risk factor for developing diabetic polyneuropathy (Andersen et al., 2018) and is correlated with PDN in patients (Bierhaus et al., 2012) . We report elevated MG-AGE in serum of db/db mice that exhibit pain-like behavior. This extends previous studies describing elevation of free MG or MG-AGE in serum of patients with diabetes (Andersen et al., 2018; Sveen et al., 2013) , the streptozotocin mouse model of type 1 diabetes (Bierhaus et al., 2012) , the Zucker Diabetic Fatty rat model of type 2 diabetes (Griggs et al., 2016) , and db/db mice (Bierhaus et al., 2012) . In non-diabetic subjects, experimental elevation of MG via repeated systemic administration of either a GLO1 inhibitor in mice (Andersson et al., 2013) , MG in rats (Liu et al., 2017) , or MG in mice (Barragan-Iglesias et al., 2018) produces pain-like hypersensitivity. This suggests that MG is sufficient to cause PDN. A likely source of elevated MG and the corresponding PDN in db/db mice is reduced GLO1 activity. Indeed, reduced GLO1 activity is reported in type 2 diabetic rats (Skapare et al., 2012) and db/db mice (Bierhaus et al., 2012) , and is associated with PDN in type 1 and type 2 diabetic patients (Skapare et al., 2013) . Interestingly, a recent study reports that upregulation of MG recapitulates the development of type 2 diabetes (Moraru et al., 2018) , supporting the idea that MG causes type 2 diabetes.
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22 Thus, pharmacotherapeutic strategies to reduce or sequester MG have the potential to mitigate the pathological complications of diabetes, including PDN.
To determine whether endogenous MG is necessary for painful diabetic neuropathy in type 2 diabetes, we used two interventions that have been validated to reduce MG and pain-like behavior in the streptozotocin model of type 1 diabetes (Bierhaus et al., 2012) . First, MG scavenging with GERP10 reduced behavioral signs of PDN in db/db mice (Figures 1, 3) , consistent with studies showing that GERP10 or other MG scavenging molecules such as aminoguanidine, metformin, or D-arginine reduce hypersensitivity in the streptozotocin model (Bierhaus et al., 2012; Huang et al., 2016) . Since our results cannot definitively distinguish a peripheral versus central site of action, further studies are needed to determine whether GERP10 crosses the blood-brain barrier in db/db mice. Nevertheless, these results provide support for the development of novel MG scavenging molecules as a pharmacotherapy for PDN that do not produce the side effects that derailed clinical trials of aminoguanidine (Thornalley, 2003) . For example, CycK(Myr)R4E exhibits a long circulatory half-life, rapid scavenging, and reduces MG-AGE and MG-evoked heat hypersensitivity in mice without noticeable side effects (Brings et al., 2017) .
Our second intervention to reduce MG, administration of a GLO1 overexpression vector, also attenuated pain-like behavior in db/db mice. This extends a previous study showing that administration of the same GLO1 overexpression vector reduced MG, increased activity of GLO1 in sciatic nerve, and attenuated hyperalgesia in the streptozotocin model (Bierhaus et al., 2012) . Other studies indicate a critical contribution of GLO1 activity in PDN. For example, copy number of the GLO1 gene, elevated in BALB/cByJ mice as compared to closely related BALB/cJ mice, is positively correlated with both GLO1 expression and reduction of streptozotocininduced peripheral neuropathy (Jack et al., 2012) . Similarly in diabetic patients, minor allele single nucleotide polymorphisms in GLO1 are linked to decreased GLO1 activity (Peculis et al., 2013) and reduced GLO1 activity is associated with PDN (Skapare et al., 2013) , suggesting that decreased GLO1 in a subset of diabetic patients could be a risk factor for developing PDN. This work provides a strong rationale for ongoing research aiming to develop new strategies that promote GLO1 activity so as to alleviate PDN in type 2 diabetes. For example, activators of the transcription factor Nrf2 promotes expression of GLO1, protecting against MGmediated DNA and protein damage in cultured Hep2G cells (Xue et al., 2012) . In patients, co-administration of
trans-resveratrol and hesperatin increased GLO1 expression and decreased MG by activating Nrf2. (Xue et al., 2016) . In db/db mice, the Nrf2 activator sulforaphane alleviated pain-like mechanical hypersensitivity (McDonnell et al., 2017) , further supporting Nrf2 as a target for treating PDN in type 2 diabetes. Taken together, these results suggest that endogenous GLO1 is important for protecting against MG-associated PDN.
MG-evoked spinal nociceptive transmission is increased in type 2 diabetes
Neuropathic pain associated with type 2 diabetes remains a difficult condition to treat, in part because the central mechanisms that generate and maintain PDN require further study. To this end, we show that intrathecal administration of MG is sufficient to produce hyperalgesia. This extends previous reports that intraplantar, systemic, and intravenous administration of MG evokes hyperalgesia on a similar time scale (Andersson et al., 2013; Bierhaus et al., 2012; Griggs et al., 2017; Huang et al., 2016; Liu et al., 2017) , and is consistent with pain-like behavior evoked by intrathecal MG administration in rats (Liu et al., 2017; Wei et al., 2017) . We go beyond these previous studies by showing that intrathecal MG induces affective pain, as evidenced by the production of conditioned place avoidance. In addition, we report that MG increases calcium mobilization in neurons within lamina II of the dorsal horn. This is consistent with MG-evoked calcium mobilization in peripheral sensory neurons isolated from the dorsal root ganglia (Andersson et al., 2013; Eberhardt et al., 2012) . These results suggest that MG activates nociceptive neurons at both spinal and peripheral sites to drive nociceptive transmission in diabetes.
The current results support the hypothesis that MG facilitates central sensitization in the spinal cord to produce pain in type 2 diabetic mice. Compared to control BKS mice, MG-evoked calcium responses were exacerbated in db/db, indicating sensitization of a spinal signaling mechanism that is responsive to MG. This is consistent with the induction of long-term potential of C-fiber-evoked field potentials by local application of MG to the rat spinal dorsal horn (Wei et al., 2017) . Further supporting a spinal site of action for endogenous MGevoked pain, intrathecal administration of: 1) aminoguanidine reduced elevated spinal MG and pain in a rat model of lumbar disk herniation (Liu et al., 2017) ; 2) metformin, a first line treatment for type 2 diabetes and a putative MG scavenger (Kender et al., 2014) , reduced bortezomib-induced increases in spinal MG levels (Wei et al., 2017) ; and 3) GERP10 attenuated pain-like behavior in db/db (current results). Since GLO1 activity is could recapitulate a physiologically relevant increase (5-10 fold) in plasma MG reported in PDN patients (Bierhaus et al., 2012) . Nevertheless, to address this limitation of our intrathecal MG model, we conducted corollary studies in the db/db model of PDN in type 2 diabetes.
A spinal TRPA1-AC1-PKA/Epac cascade contributes to MG-evoked pain during type 2 diabetes
TRPA1
Previous studies suggest that peripheral TRPA1 channels mediate streptozotocin-induced hyperalgesia (Wei et al., 2009) , but this interpretation was confounded by recent evidence that streptozotocin directly activates TRPA1 (Andersson et al., 2015) , and thus required validation in a model of type 2 diabetes (Feldman et al., 2017) . Our approach using intrathecal MG and db/db models avoided these pitfalls and demonstrated that pharmacological or genetic inhibition of spinal TRPA1 reduced pain-like behavior. This indicates that spinal MG-TRPA1 activity contributes to neuropathic pain associated with type 2 diabetes. The spinal TRPA1 
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25 site of action is unclear, but could be at the central terminals of the primary afferent neuron or involve astrocytes. Astrocytic TRPA1 was previously shown to regulate basal calcium in astrocytes (Shigetomi et al., 2011) and contribute to long-term potentiation in the hippocampus (Shigetomi et al., 2013) . TRPA1immunoreactivity is present in the spinal dorsal root, suggesting transport from the DRG to central terminals (Anand et al., 2008) . Furthermore, activity-dependent release of the reactive metabolites 5,6-EET (Sisignano et al., 2012) or HxA3 (Gregus et al., 2012) or superfusion of AITC (Sisignano et al., 2012) 
AC1
Spinal AC1 contributes to latent pain sensitization and the spinal mechanisms of chronic pain (Corder et al., 2013; Wang et al., 2011) . We now report that either intrathecal administration of the AC1 inhibitor NB001 or genetic deletion of AC1 prevented mechanical hypersensitivity induced by intrathecal MG. Furthermore, intrathecal NB001 attenuated pain-like behavior in db/db mice, implicating AC1 in the maintenance of PDN in type 2 diabetes. NB001 also inhibits pain associated with nerve injury (Wang et al., 2011) or inflammation (Corder et al., 2013) , probably through reducing the AC1-mediated overproduction of cAMP and its downstream signaling in response to painful stimulation (Corder et al., 2013) . Although we did not measure spinal cAMP in db/db or after intrathecal MG, intrathecal administration of a pan AC inhibitor attenuated elevated cAMP in the spinal cord and pain-like behavior in Zucker Diabetic Fatty rats (Feng et al., 2017) .
Taken together, these results suggest that spinal AC1 superactivity contributes to PDN in type 2 diabetes. (Aley and Levine, 1999; Eijkelkamp et al., 2013; Gu et al., 2016; Huang and Gu, 2017; Hucho et al., 2005; Matsuda et al., 2017; Wang et al., 2013) , including hyperalgesic priming in the DRG and peripheral nerve (Huang and Gu, 2017; Wang et al., 2013) , the contribution of spinal Epac to pain and/or whether Epacs mediate PDN remained unclear. The current findings address these gaps with the intrathecal administration of newly-developed inhibitors of Epac isoforms (Chen et al., 2013a; Chen et al., 2013b; Chen et al., 2012; Chen et al., 2014; Wang et al., 2017; Zhu et al., 2015) . Our data demonstrates inhibition of MG-evoked hypersensitivity by intrathecal administration of HJC-0350, ESI-09, and HJC-0197, extending the therapeutic targeting of Epac1/2 isoforms to the dorsal horn of the spinal cord.
PKA/Epac
Because HJC-0197 (nonselective Epac1/2 inhibitor) but not HJC-0350 (Epac2 selective inhibitor) attenuated hyperalgesia in db/db, we conclude that Epac1 is a critical isoform that contributes to spinally-mediated PDN in type 2 diabetes. This is consistent with previous studies in pain models of inflammation, nerve-injury, or plantar incision indicating that pharmacological inhibition, genetic knockout, or antisense oligodeoxynucleotide knockdown of Epac1 reduced peripherally-mediated pain-like behavior (Eijkelkamp et al., 2013; Gu et al., 2016; Matsuda et al., 2017; Wang et al., 2013) . A caveat is that knockout of Epac1 in mice and embryonic stem cells disrupts pancreatic β-cells and glucose-stimulated insulin secretion, exacerbating streptozotocininduced type 1 diabetes (Kai et al., 2013) . Perhaps new Epac inhibitors could be designed to target Epac1 at
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27 locations specific to the nervous system to avoid off-target effects within the pancreas. Nevertheless, our findings provide support for further investigation of the contribution of spinal Epac1 to PDN in type 2 diabetes.
TRPA1-AC1-PKA/Epac signaling cascade.
Our current results suggest that TRPA1 activity initiates AC1-PKA and/or AC1-Epac signaling cascades that maintain MG-evoked pain. In support of our proposed linkage between TRPA1-derived calcium, AC1, and PKA, either removal of extracellular calcium, application of an AC antagonist, or application of H-89 each blocked the potentiation of capsaicin-evoked DRG neuron activity mediated by TRPA1 (Spahn et al., 2014) . In support of Epacs as a downstream effector, AC1-derived cAMP drives inflammatory pain via peripheral Epac1/2 (Hucho et al., 2005) . We suggest that complex protein-protein interactions between intracellular effector molecules (e.g. AC, PKA, Epac) and their putative extracellular signal transduction elements (e.g. MG-TRPA1 activity) promotes hyperexcitability and pain. Interestingly, a recent study reported that the scaffolding protein A-kinase anchoring protein (AKAP) mediates phosphorylation of TRPA1 by PKA (Brackley et al., 2017) .
Furthermore, the generation of hyperalgesic priming required both TRPA1 and AKAP (Brackley et al., 2017) .
This suggests that TRPA1, AKAPs, and PKA work together to contribute to the initiation of persistent painful sensitization. AKAPs may also mediate subcellular colocalization of AC and Epacs to produce pain (Huang and Gu, 2017) . Whether the maintenance of complex protein-protein interactions by AKAPs contributes to PDN remains an interesting future direction.
Conclusions
Despite decades of research, diabetic neuropathy continues to be complicated by neuropathic pain in up to 50% of patients (Abbott et al., 2011) . The current study aimed to establish novel targets for the development of new therapies for PDN. First, we establish the therapeutic utility of MG scavengers and GLO1 enhancers in a mouse model of type 2 diabetes, extending a study in streptozotocin-evoked type 1 diabetes (Bierhaus et al., 2012) . This is important because prior preclinical studies of PDN tended not to distinguish between type 1 and type 2 patient classes (Callaghan et al., 2012a; Feldman et al., 2017) , despite the fact that rigorous glycemic control reduces neuropathy in type 1 but not type 2 diabetic patients (Callaghan et al., 2012b) . Second, our A C C E P T E D M A N U S C R I P T 28 results are the first to identify multiple targets within the spinal cord (e.g. the inhibition of MG, TRPA1, AC1, Epac) as potential therapies for PDN associated with type 2 diabetes. This is in line with a recent report highlighting the need to identify the central mechanisms that drive neuropathic pain in diabetes (Feldman et al., 2017) .
Our results indirectly support the combination of resveratrol and hesperatin treatment for PDN, as this induces GLO1 activity in patients (Xue et al., 2016) , as well as metformin, an FDA-approved anti-diabetic treatment, which acts as an MG scavenger to reduce MG levels in type 2 diabetic patients (Beisswenger et al., 1999; Kender et al., 2014) and attenuates pain-like behavior in streptozotocin rats (Ma et al., 2015) .
Interestingly, a recent study indicates that metformin ameliorates both the upregulation of DRG membrane TRPA1 and hypersensitivity in db/db (Wang et al., 2018) , adding support to targeting TRPA1 inhibition as a pharmacotherapy for PDN in type 2 diabetes. We conclude that MG produces evoked hypersensitivity and affective pain, and sensitization of a spinal TRPA1-AC1-Epac signaling cascade facilitates hyperalgesia in db/db mice, supporting further clinical study of agents targeting this pathway in type 2 diabetic patients with pain. 
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